share_log

Jo-Jo Capital Canada Ltd. Enters Into Letter of Intent to Complete Qualifying Transaction With 9302204 Canada Inc. (O/a Cheelcare)

Jo-Jo Capital Canada Ltd. Enters Into Letter of Intent to Complete Qualifying Transaction With 9302204 Canada Inc. (O/a Cheelcare)

Jo-Jo Capital Canada Ltd. 与 9302204 Canada Inc.(o/a Cheelcare)签订了完成合格交易的意向书
GlobeNewswire ·  01/25 08:00

NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. THIS NEWS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY OF THE SECURITIES IN THE UNITED STATES. THE SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT") OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED UNDER THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE. THIS NEWS RELEASE DOES NOT CONSTITUTE AN OFFER OR SALE OF SECURITIES IN THE UNITED STATES.

不用于向美国电报社分发或在美国传播。本新闻稿不构成美国任何证券的卖出要约或收购要约的邀请。这些证券过去和将来都不会根据经修订的1933年《美国证券法》进行注册( “美国证券法”)或任何州证券法,除非根据《美国证券法》和适用的州证券法进行注册或获得此类注册的豁免,否则不得在美国境内或向美国个人发行或出售。本新闻稿不构成在美国的证券要约或出售。

TORONTO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Jo-Jo Capital Canada Ltd. ("Jo-Jo") is pleased to announce that it has entered into a binding letter of intent dated January 24, 2024 (the "LOI") with 9302204 Canada Inc. (o/a Cheelcare) ("Cheelcare") pursuant to which Jo-Jo proposes to acquire all of the issued and outstanding securities of Cheelcare in exchange for the issuance of securities of Jo-Jo, which will result in Cheelcare becoming a wholly-owned subsidiary of Jo-Jo (the "Cheelcare Transaction"). The Cheelcare Transaction, assuming the completion of the Private Placement (as defined below), will result in a reverse take-over of Jo-Jo where the existing shareholders of Cheelcare will own a majority of the outstanding common shares of Jo-Jo (the "Jo-Jo Common Shares") and Jo-Jo is expected be renamed, subject to shareholder approval, to such name as Cheelcare may determine (the "Resulting Issuer"). Upon completion of the Cheelcare Transaction, it is anticipated that the Resulting Issuer will be a Technology Issuer.

多伦多,2024年1月24日(GLOBE NEWSWIRE)——加拿大Jo-Jo资本有限公司(“Jo-Jo”)欣然宣布,它已于2024年1月24日与9302204 Canada Inc.(o/a Cheelcare)(“Cheelcare”)签订了具有约束力的意向书(“LOI”),根据该意向书,Jo-Jo提议收购Cheelcare的所有已发行和流通证券以换取Jo-Jo发行证券,这将使Cheelcare成为Jo-Jo的全资子公司(“Cheelcare交易”)。假设私募股权配售已经完成(定义见下文),Cheelcare交易将导致对Jo-Jo的反向收购,Cheelcare的现有股东将拥有Jo-Jo的大部分已发行普通股(“Jo-Jo普通股”),经股东批准,预计Jo-Jo将重命名为Cheelcare可能确定的名称(“最终发行人”)。Cheelcare交易完成后,预计最终发行人将成为技术发行人。

Trading in the Jo-Jo Common Shares will be halted in accordance with the policies of the TSX Venture Exchange (the "TSXV") and will remain halted until such time as all required documentation in connection with the Cheelcare Transaction has been filed with and accepted by the TSXV and permission to resume trading has been obtained from the TSXV.

根据多伦多证券交易所风险交易所(“多伦多证券交易所”)的政策,Jo-Jo普通股的交易将暂停,并将一直暂停,直到与Cheelcare交易有关的所有所需文件已提交并获得多伦多证券交易所接受并获得多伦多证券交易所恢复交易的许可。

The Qualifying Transaction

符合条件的交易

Jo-Jo is a capital pool company and intends that the Cheelcare Transaction will constitute its "Qualifying Transaction" under Policy 2.4 – Capital Pool Companies of the TSXV ("Policy 2.4"). The Cheelcare Transaction will not constitute a non-arm's length qualifying transaction or a related party transaction pursuant to the policies of the TSXV.

Jo-Jo是一家资本池公司,打算将Cheelcare交易构成其 “合格交易” 政策 2.4 — 资本池公司 多伦多证券交易所(“政策2.4”)。根据多伦多证券交易所的政策,Cheelcare交易不构成非正常交易或关联方交易。

Pursuant to the terms and conditions of the LOI, Jo-Jo and Cheelcare will negotiate and enter into a definitive agreement (the "Definitive Agreement") incorporating the principal terms of the Cheelcare Transaction as described in the LOI and this press release. There is no assurance that a Definitive Agreement will be successfully negotiated or entered into. The terms and conditions outlined in the LOI are binding on the parties and the LOI is expected to be superseded by the Definitive Agreement to be negotiated between the parties. The Cheelcare Transaction will be structured as a share exchange, plan of arrangement, amalgamation or other form of business combination based on the advice of the parties' respective advisors and taking into account various securities, tax, operating and other considerations.

根据意向书的条款和条件,Jo-Jo和Cheelcare将谈判并签订最终协议(“最终协议”),其中纳入意向书和本新闻稿中描述的Cheelcare交易的主要条款。无法保证最终协议会成功谈判或签订。意向书中概述的条款和条件对双方具有约束力,预计意向书将被双方谈判的最终协议所取代。Cheelcare交易将根据双方各自顾问的建议,并考虑到各种证券、税收、运营和其他考虑因素,以股票交易所、安排计划、合并或其他形式的业务合并为结构。

As consideration for the acquisition of all of the outstanding securities of Cheelcare, holders of issued and outstanding common shares of Cheelcare ("Cheelcare Common Shares") will receive one (1) post-consolidation Jo-Jo Common Share for each one (1) post-Cheelcare Split Cheelcare Common Share.

作为收购Cheelcare所有已发行证券的对价,Cheelcare已发行和流通普通股(“Cheelcare普通股”)的持有人将在合并后每股Cheelcare拆分Cheelcare普通股获得一(1)股Jo-Jo普通股。

Immediately prior to the completion of the Cheelcare Transaction, it is anticipated that, Jo-Jo will consolidate its issued and outstanding Jo-Jo Common Shares on the basis of two (2) pre-consolidation Jo-Jo Common Shares for each one (1) post-consolidation Jo-Jo Common Share (the "Jo-Jo Consolidation Ratio") as a condition to the completion of the Cheelcare Transaction (the "Jo-Jo Consolidation"). Currently there are 8,198,750 Jo-Jo Common Shares issued and outstanding. All incentive stock options and outstanding warrants of Jo-Jo are anticipated to be adjusted on the basis of the Jo-Jo Capital Consolidation Ratio.

预计在Cheelcare交易完成之前,Jo-Jo将在合并后每股一(1)股合并后的Jo-Jo普通股(“Jo-Jo合并比率”)的两(2)股合并前合并其已发行和流通的Jo-Jo普通股,合并其已发行和流通的Jo-Jo普通股,以此作为Cheelcare交易(“Jo-Jo合并”)完成的条件。目前,共发行和流通了8,198,750股Jo-Jo普通股。Jo-Jo的所有激励性股票期权和未偿还认股权证预计将根据Jo-Jo资本整合比率进行调整。

In addition, immediately prior to the completion of the Cheelcare Transaction, Cheelcare will split its issued and outstanding Cheelcare Common Shares on such basis as shall result in Cheelcare having 34,000,000 Cheelcare Common Shares (the "Cheelcare Share Split Ratio") issued and outstanding following completion of the split, excluding any securities issued in the Private Placement (as defined below) and the Debenture Conversion (as defined below) as a condition to the completion of the Cheelcare Transaction (the "Cheelcare Split"). There are currently 8,005,690 Cheelcare Common Shares issued and outstanding. All incentive stock options of Cheelcare are anticipated to be adjusted on the basis of the Cheelcare Share Split Ratio.

此外,在Cheelcare交易完成之前,Cheelcare将分割其已发行和流通的Cheelcare普通股,这将使Cheelcare在拆分完成后发行和流通的34,000,000股Cheelcare普通股(“Cheelcare股票分割比率”),不包括以私募方式(定义见下文)和债券转换(定义见下文)中发行的任何证券完成Cheelcare交易(“Cheelcare拆分”)的条件。目前已发行和流通的Cheelcare普通股为8,005,690股。预计Cheelcare的所有激励性股票期权都将根据Cheelcare的股票分割比率进行调整。

Cheelcare intends to conduct, and it is a condition of the Cheelcare Transaction for Cheelcare to close, a concurrent private placement (the "Private Placement") for minimum aggregate gross proceeds of C$2,500,000 through the offering of subscription receipts of Cheelcare to be sold at an issue price of C$0.25, the terms of which are currently being negotiated. Subject to the satisfaction of certain customary conditions, it is anticipated the subscription receipts shall automatically convert into Cheelcare Common Shares on a post-Cheelcare Split basis. Further disclosure of the terms and conditions of the Private Placement will be provided upon the successful negotiation and the terms and conditions thereof. There is no assurance that such negotiations will be concluded successfully. Cheelcare intends to use the net proceeds from the Private Placement for business development, working capital requirements and general corporate purposes.

Cheelcare打算同时进行私募配售(“私募配售”),通过发行Cheelcare的认购收据,以0.25加元的发行价出售,同时进行私募配售(“私募配售”),以0.25加元的发行价出售,其条款目前正在谈判中。在满足某些惯例条件的前提下,预计认购收据将在CheelCare拆分后的基础上自动转换为Cheelcare普通股。在谈判成功后,将进一步披露私募的条款和条件及其条款和条件。无法保证此类谈判会成功结束。Cheelcare打算将私募的净收益用于业务发展、营运资金要求和一般公司用途。

Significant Conditions to Closing

关闭的重要条件

The completion of the Cheelcare Transaction is subject to a number of conditions precedent, including but not limited to satisfactory due diligence review, negotiation and execution of the Definitive Agreement and accompanying transaction documents, approval by the boards of directors of each of Jo-Jo and Cheelcare, approval of the shareholders of each of Jo-Jo and Cheelcare (if required), obtaining necessary third party approvals, TSXV acceptance, closing of the Private Placement for gross proceeds of not less than C$2,500,000 and preparation and filing of a management information circular or filing statement outlining the definitive terms of the Cheelcare Transaction and describing the business to be conducted by the Resulting Issuer following completion of the Cheelcare Transaction, in accordance with the policies of the TSXV. There can be no assurance that the Cheelcare Transaction or the Private Placement will be completed as proposed, or at all. The obligations of Jo-Jo and Cheelcare pursuant to the LOI shall terminate in certain specified circumstances, including but not limited to in the event that a Definitive Agreement is not entered into between the parties by February 29, 2024.

Cheelcare交易的完成需要满足一些先决条件,包括但不限于令人满意的尽职调查审查、最终协议和随附交易文件的谈判和执行、Jo-Jo和Cheelcare各自董事会的批准、Jo-Jo和Cheelcare各股东的批准(如果需要)、获得必要的第三方批准、TSXV的接受、总收益的私募结束不少于 2,500,000 加元,并准备和提交管理信息通告或申报声明,概述了Cheelcare交易的最终条款,并描述了最终发行人在Cheelcare交易完成后将根据多伦多证券交易所的政策开展的业务。无法保证Cheelcare交易或私募会按提议完成,或者根本无法保证。Jo-Jo和Cheelcare根据意向书承担的义务将在某些特定情况下终止,包括但不限于双方在2024年2月29日之前未签订最终协议的情况。

Additionally, it is a condition of the Cheelcare Transaction for Cheelcare to convert $1,133,300 principal amount in unsecured convertible debentures outstanding into Cheelcare Shares at a conversion price which is at a 25% discount to the valuation ascribed to the Cheelcare Shares in the Cheelcare Transaction (the "Debenture Conversion").

此外,Cheelcare交易的条件是将本金1,133,300美元的已发行无抵押可转换债券转换为Cheelcare股票,其转换价格比Cheelcare交易(“债券转换”)中Cheelcare股票的估值折扣25%。

This is an initial press release. Jo-Jo plans to issue a comprehensive press release in accordance with Policy 2.4 once it has entered into the Definitive Agreement to provide, among other things, selected information respecting Cheelcare, the Private Placement and the biographies of the anticipated directors and officers of the Resulting Issuer. Additional information with respect to Cheelcare and the Transaction will be included in the Company's management information circular or filing statement to be filed in connection with the Transaction, which will be available under Jo-Jo's SEDAR profile at .

这是最初的新闻稿。Jo-Jo计划在签订最终协议后根据政策2.4发布一份全面的新闻稿,除其他外,提供有关Cheelcare、私募以及最终发行人的预期董事和高级管理人员简历的精选信息。有关Cheelcare和本次交易的更多信息将包含在公司提交的与该交易相关的管理信息通告或申报声明中,该通告或申报声明将在Jo-Jo的SEDAR个人资料下提供,网址为。

Sponsorship

赞助

Sponsorship of a Qualifying Transaction is required by the TSXV unless a waiver from the sponsorship requirement is obtained. Jo-Jo intends to apply for a waiver from sponsorship for the Cheelcare Transaction. There is no assurance that a waiver from this requirement will be obtained.

除非获得赞助要求的豁免,否则多伦多证券交易所要求赞助合格交易。Jo-Jo打算为Cheelcare交易申请赞助豁免。无法保证会获得对这一要求的豁免。

About 9302204 Canada Inc. (o/a Cheelcare)

关于 9302204 加拿大公司(o/a Cheelcare)

9302204 Canada Inc. (o/a CheelcareTM) is a company incorporated under the Canada Business Corporations Act and stands as an innovative technological and manufacturing company dedicated to removing barriers to mobility. By harnessing the power of artificial intelligence and breakthrough engineering, Cheelcare is determined to radically improve the lives of millions living with disabilities by delivering next-generation, life-changing technology to the multi-billion wheelchair market. Innovations that are not just a step forward but a leap into uncharted territories that redefine possibilities. Cheelcare's alignment with government funding programs ensures that customers can access its critical products through resilient funding streams, even in diverse market conditions.

9302204 加拿大公司 (o/a Cheelcare)TM)是一家根据《加拿大商业公司法》注册成立的公司,是一家致力于消除出行障碍的创新技术和制造公司。通过利用人工智能和突破性工程的力量,Cheelcare决心通过向数十亿美元的轮椅市场提供改变生活的下一代技术,从根本上改善数百万残疾人的生活。创新不仅是向前迈出的一步,而且是向未知领域的飞跃,重新定义了可能性。Cheelcare与政府资助计划保持一致,确保即使在不同的市场条件下,客户也可以通过弹性资金流获得其关键产品。

Cheelcare's portfolio includes three rapidly growing lines of patented devices: innovative safety accessories, the industry-award-winning power add-on for manual wheelchairs known as Companion, and Curio, a technologically advanced robotic complex rehab power wheelchair.

Cheelcare的产品组合包括三种快速增长的专利设备系列:创新的安全配件、业界获奖的名为Companion的手动轮椅电动附加组件,以及技术先进的复杂机器人康复电动轮椅Curio。

Curio sets new industry benchmarks with an unprecedented range of movement, omnidirectional tilting, and self-levelling capabilities – pioneering a new dimension in mobility.

Curio 凭借前所未有的运动范围、全向倾斜和自平衡能力设定了新的行业基准,开创了出行的新维度。

Cheelcare is redefining accessibility for millions. Its team of engineers and visionaries is on a mission to continuously expand its life-changing impact in the global market.

Cheelcare正在重新定义数百万人的可访问性。其工程师和远见卓识团队的使命是不断扩大其在全球市场上改变生活的影响。

About Jo-Jo Capital Canada Ltd.

关于 Jo-Jo Capital Canada Ltd

Jo-Jo is a capital pool company created pursuant to the policies of the TSXV. It does not own any assets, other than cash or cash equivalents and its rights under the LOI. The principal business of Jo-Jo is to identify and evaluate opportunities for the acquisition of an interest in assets or businesses and, once identified and evaluated, to negotiate an acquisition or participation subject to acceptance by the TSXV so as to complete a Qualifying Transaction in accordance with Policy 2.4.

Jo-Jo是一家根据多伦多证券交易所的政策创建的资本池公司。除了现金或现金等价物及其在意向书下的权利外,它不拥有任何资产。Jo-Jo的主要业务是确定和评估收购资产或企业权益的机会,并在确定和评估后,就收购或参与进行谈判,但须经多伦多证券交易所接受,以便根据政策2.4完成合格交易。

Forward-Looking Statements Disclaimer

前瞻性声明免责声明

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多伦多证券交易所风险投资交易所及其监管服务提供商(该术语在多伦多证券交易所风险投资交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Jo-Jo assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to Jo-Jo. Additional information identifying risks and uncertainties is contained in filings by Jo-Jo with the Canadian securities regulators, which filings are available at .

本新闻稿中的某些信息可能包含前瞻性陈述。这些信息基于当前的预期,这些预期存在难以预测的重大风险和不确定性。实际结果可能与任何前瞻性陈述中建议的结果存在重大差异。除非适用于Jo-Jo的证券法有要求,否则Jo-Jo没有义务更新前瞻性陈述,也没有义务更新实际业绩可能与前瞻性陈述中反映的结果不同的原因。识别风险和不确定性的其他信息包含在Jo-Jo向加拿大证券监管机构提交的文件中,这些文件可在以下网址查阅

Completion of the Cheelcare Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and, if applicable pursuant to TSXV requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.

Cheelcare交易的完成取决于许多条件,包括但不限于多伦多证券交易所的接受,以及根据多伦多证券交易所的要求,还需要获得大多数少数股东的批准。在适用的情况下,在获得所需的股东批准之前,交易无法完成。无法保证交易会按提议完成或根本无法保证。

Investors are cautioned that, except as disclosed in the filing statement or management information circular to be prepared in connection with the Cheelcare Transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

提醒投资者,除非在与Cheelcare交易相关的申报声明或管理信息通告中披露的内容,否则发布或收到的有关该交易的任何信息可能不准确或不完整,不应作为依据。资本池公司的证券交易应被视为高度投机性。

The TSXV has in no way passed upon the merits of the proposed Cheelcare Transaction and has neither approved nor disapproved the contents of this press release.

多伦多证券交易所根本没有透露拟议的Cheelcare交易的优点,也没有批准或不批准本新闻稿的内容。

The Jo-Jo Common Shares will remain halted until such time as permission to resume trading has been obtained from the TSXV. Jo-Jo is a reporting issuer in Alberta, British Columbia, and Ontario.

在获得多伦多证券交易所恢复交易的许可之前,Jo-Jo普通股将保持暂停状态。Jo-Jo是艾伯塔省、不列颠哥伦比亚省和安大略省的申报发行人。

For more information about Jo-Jo, please contact Peter Schloo, Chief Executive Officer, at (905) 505-0918.

有关Jo-Jo的更多信息,请致电 (905) 505-0918与首席执行官彼得·施洛联系。


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发